Similarly, combining TLR4/NF-κB and Nrf2-ARE pathway modulation offers a comprehensive approach to managing IBD by simultaneously reducing inflammation and enhancing antioxidant defenses. Here, TLR4 is linked to inflammatory bowel disease.